PT-141 (Bremelanotide)
Bremelanotide (PT-141) is FDA-approved as Vyleesi for a specific medical indication.
What it is
PT-141, or bremelanotide, is a melanocortin-receptor agonist and one of the genuine FDA-approved drugs in this library: it is sold as Vyleesi, approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
That approval rests on controlled trials with characterized side effects — nausea being the most common. The gray market sells PT-141 far beyond the approved indication, mostly to men, a use the approval evidence does not cover.
What researchers have actually studied it for
Hypoactive sexual desire disorder in premenopausal women — its FDA-approved indication — plus earlier erectile-function research.
How it works
Bremelanotide activates melanocortin receptors (chiefly MC4R) in brain circuits involved in sexual desire — a central-nervous-system mechanism, unlike the blood-flow route of PDE5 drugs. It descends chemically from melanotan II, with the pigmentation activity dialed down but not to zero.
Where it came from
Its origin story is pharmacology folklore: University of Arizona tanning-peptide research in the 1990s produced unexpected sexual side effects, spinning out both melanotan II's gray-market career and bremelanotide's legitimate one. After an intranasal blood-pressure setback and reformulation, FDA approval came in 2019.
What the research record actually contains
- RECONNECT phase 3 trials: statistically significant desire and distress improvements versus placebo in the approved population.
- Earlier erectile-function studies (male use) that were not carried to approval.
- Post-market experience since 2019 within the approved indication.
What's known about risks
Trial-documented: nausea in roughly 40% of users (the headline tolerability issue), flushing, headache, transient blood-pressure rises (contraindicated in uncontrolled hypertension), and focal skin darkening with frequent use — the melanocortin heritage showing through.
Where it stands legally
Prescription drug (Vyleesi) for its approved indication; anything outside that — including the male-market vials online — is either off-label medicine (prescriber territory) or unregulated gray market (no one's territory).
Worth asking a licensed provider
- 1.Does my situation match the approved indication, or would this be off-label?
- 2.Is my blood pressure compatible with a melanocortin agonist?
- 3.What non-drug and established-drug options should we consider first?